ELISA Kit for Hepcidin (Hepc)

Format

48T, 96T, 96T×5, 96T×10, 96T×100

Detection range

320-200,000pg/mL

Application

Enzyme-linked immunosorbent assay for Antigen Detection.

Organism species

Homo sapiens (Human)

Sensitivity

The minimum detectable dose of this kit is typically less than 112pg/mL

Sample type

Serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids

Assay length

2h

Method

Competitive Inhibition

Test principle

This assay employs the competitive inhibition enzyme immunoassay technique. A monoclonal antibody specific to Hepcidin (Hepc) has been pre-coated onto a microplate. A competitive inhibition reaction is launched between biotin labeled Hepcidin (Hepc) and unlabeled Hepcidin (Hepc) (Standards or samples) with the pre-coated antibody specific to Hepcidin (Hepc). After incubation the unbound conjugate is washed off. Next, avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. The amount of bound HRP conjugate is reverse proportional to the concentration of Hepcidin (Hepc) in the sample. After addition of the substrate solution, the intensity of color developed is reverse proportional to the concentration of Hepcidin (Hepc) in the sample.

Alternative Names

HAMP; HFE2B; PLTR; LEAP1; Hepcidin Antimicrobial Peptide; Liver-expressed antimicrobial peptide 1; Putative liver tumor regressor

Item Name

Hepcidin

Research Area

Metabolic pathway;Endocrinology;Hematology;Genetic science;

Reference

Serum iron metabolism markers including hepcidin in multiple sclerosis patients;Monitoring Hepcidin Level in Chronic Hepatitis C Virus Patients during Therapy;Hepcidin and regulation of iron homeostasis in maintenance hemodialysis patients;The interplay among iron metabolism, endothelium and inflammatory cascade in dysmetabolic disorders;An Evaluation of the Correlation between Hepcidin Serum Levels and Disease Activity in Inflammatory Bowel Disease;Serum hepcidin levels in Bulgarian population.;Liver Congestion in Heart Failure Contributes to Inappropriately Increased Serum Hepcidin despite Anemia;Hepcidin regulation in prostate and its disruption in prostate cancer;Effect of a More Permeable Dialysis Membrane on ESA Resistance in Hemodialysis Patients - A Pilot Investigation;Urinary Hepcidin in Diagnosis of Iron Deficiency Anemia;Hepcidin in tumor‐related iron deficiency anemia and tumor‐related anemia of chronic disease: pathogenic mechanisms and diagnosis;The Effects of Treatment on Serum Hepcidin and Iron Homeostasis in HIV-1-Infected In-dividuals;Hydrogen sulfide attenuates inflammatory hepcidin by reducing IL-6 secretion and promoting SIRT1-mediated STAT3 deacetylation;Acidic Polysaccharide from Angelica sinensis Reverses Anemia of Chronic Disease Involving the Suppression of Inflammatory Hepcidin and NF-κB Activation;Evaluation of a competitive hepcidin ELISA assay in the differential diagnosis of iron deficiency anaemia with concurrent inflammation and anaemia of inflammation in elderly patients;AMPK serves as a Therapeutic Target against Anemia of Inflammation;Hepcidin suppression in β‑thalassemia is associated with the down‑regulation of atonal homolog 8;Modulation of iron status biomarkers in tuberculosis-diabetes co-morbidity;The Role of Insulin Therapy in Correcting Hepcidin Levels in Patients with Type 2 Diabetes Mellitus.;Increased NGAL level associated with iron store in chronic kidney disease with anemia;Relationship between obesity and iron deficiency anemia: is there a role of hepcidin?;Hepcidin serum levels in HCV chronically mono-infected naïve patients, compared to healthy individuals;